Instil Bio doses first patient with ITIL-306 CoStAR-TIL in Phase 1 NSCLC trial

Instil Bio, Inc.

First patient dosed in Phase 1 study of ITIL-306, a CoStAR-engineered TIL therapy targeting FRα in non-small cell lung cancer.
ITIL-306 designed to enhance TIL activity in tumor microenvironment and eliminate need for high-dose IL-2.
Initial clinical data from dose escalation cohorts expected in 2023.
Phase 1 open-label multicenter study also includes ovarian and renal cell carcinoma patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.